Purpose Autoimmune diseases are a common cause of delayed wound healing and should be considered in patients with chronic wounds who do not respond to local wound care or who fail skin grafting in the absence of infection. Recent Findings Epidemiologic studies have shown that, of patients with chronic wounds evaluated in specialized wound healing clinics, 20-23 % have autoimmune etiologies for their wounds including vasculitis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, pyoderma gangrenosum, and other autoimmune diseases. Summary In this article, autoimmune diseases known to be associated with chronic wounds and delayed wound healing are reviewed and the importance of a multidisciplinary approach for patients with chronic wounds, with involvement of rheumatology and dermatology, is highlighted. This approach allows for investigation of underlying systemic disease and improves clinical outcomes for many of these challenging patients.
Introduction
Chronic wounds are a major public health issue, affecting approximately 6.5 million people in the USA with costs estimated at $25 billion per year [1] . These wounds significantly impact mortality [2] , psychosocial well-being, and quality of life [3] . While large epidemiologic studies show that up to 79.7 % of leg ulcers have a vascular etiology [4] (venous, peripheral arterial disease, or mixed), approximately 6.6 % of patients presenting to a dermatology clinic with chronic wounds have associated autoimmune disease [5] . Similar epidemiologic studies conducted in dedicated wound healing clinics have found that up to 20-23 % of patients with chronic wounds have associated autoimmune diseases including vasculitis, rheumatoid arthritis, scleroderma, systemic lupus erythematous, psoriasis, and pyoderma gangrenosum [4, 6•] .
Normal Wound Healing
In normal healing, wounds progress through four overlapping phases: hemostasis, inflammation, proliferation, and remodeling in order to restore epithelial integrity [7] . Chronic wounds, however, are often arrested in the inflammatory phase [7] and are unable to transition to the proliferation phase with concurrent upregulation of angiogenesis and matrix deposition. Underlying systemic immune diseases can contribute to delayed wound healing, and these diseases should be considered in chronic wounds that are arrested in the inflammatory phase. In this review, the autoimmune diseases and prothrombotic states that are known to be associated with delayed wound healing will be reviewed and the data to support along with data to support targeted biologic therapy for these patients will be discussed.
results in damage to mural structures and compromises vascular integrity and luminal flow leading to downstream tissue injury. Vasculitis can cause skin ulceration and delayed wound healing. Types of cutaneous vasculitis may be classified into primary vasculitic diseases such as in polyarteritis nodosa or secondary to another autoimmune disease such as rheumatoid arthritis (RA), scleroderma (SSc), or systemic lupus erythematosus (SLE). Vasculitides are also categorized according to the size of the vessels affected.
For the purposes of this review, causes of cutaneous ulceration related to secondary forms of vasculitis associated with autoimmune diseases including RA, SSc, and SLE will be reviewed first. Primary vasculitides and vasculitides associated with infectious etiologies will next be discussed, and finally, the features of some of the vasculitis mimics and vasculopathic processes that should be considered when evaluating a patient with delayed wound healing will be reviewed.
Rheumatoid Arthritis-Associated Leg Ulcers and Rheumatoid Vasculitis
RA is one of the most common autoimmune diseases affecting 1 % of the population. Leg ulcers occur in approximately 4.4 % of patients with RA [8] . Wounds associated with RA are usually attributed to cutaneous vasculitis [9] . An epidemiologic study from the Mayo Clinic found that ulcers occur at a rate of 1.8 leg ulcers per 100 person-years in a population of 813 RA patients followed for 9771 person-years [10•] . In this study, 6 % of ulceration episodes ultimately required amputation, and in the RA population, leg ulcers were associated with increased mortality (HR 2.42; 95 % CI 1.71, 3.42). Leg ulcers in this RA population were associated with age (HR 1.73 per 10-year increase; 95 % CI 1.47, 2.04), rheumatoid factor positivity (HR 1.63; 95 % CI 1.05, 2.53), presence of rheumatoid nodules (HR 2.14; 95 % CI 1.39, 3.31), and venous thromboembolism (HR 2.16; 95 % CI 1.07, 4.36).
While clinicians often delay escalating immunotherapy in patients with RA-associated leg ulcers due to concerns regarding risks of infection and delayed wound healing, this concern is not supported by evidence. Studies show that while glucocorticoids may predispose to skin fragility and thus serve as a risk factor for ulceration in patients with RA, more aggressive therapy for the underlying RA using disease-modifying antirheumatic drugs (DMARD) and biologic agents such as TNF-α inhibitors and rituximab as treatment for RAassociated leg ulcers is beneficial and often results in healing [8, [11] [12] [13] . In a large series investigating postoperative wound dehiscence in surgical patients, prior use of steroids or immunosuppressive drugs in the 100 days prior to the index surgery was not a risk factor for postoperative wound dehiscence [14•] , suggesting that steroid therapy may not be a direct risk factor for wound development. The association between steroid use and chronic wounds in RA patients is more likely related to the known association between RA severity and ulceration, since patients with more advanced disease, and thus predisposed to vasculitic wounds, are more likely to be on chronic corticosteroids [10•] . In patients with leg ulcers and underlying RA, referral to rheumatology and evaluation for escalation of RA therapy are warranted.
Systemic Lupus Erythematosus
Up to 5.6 % of patients with SLE [15] develop leg ulceration [16] . In a study of 340 patients with chronic wounds evaluated in a tertiary wound center, 2.6 % had underlying SLE (compared to a reported SLE prevalence of 0.05-0.15 % in the general population, p < 0.001) [6•] . Similar to RAassociated leg ulcers, ulceration in lupus patients may be secondary to immune complex-mediated vasculitis. Histologic examination of wounds in SLE shows a leukocytoclastic vasculitis with fibrinoid necrosis of the vessel wall and prominent polymorphonuclear cell infiltration. Coexistent prothrombotic states such as anti-phospholipid syndrome may also play a role in some patients [17, 18] , and thromboocclusive histologic findings should prompt additional workup [5] . Treatment of wounds in patients with SLE should focus on the management of the underlying autoimmune and inflammatory disease. Active vasculitis requires aggressive therapy with corticosteroids and steroid-sparing DMARD agents. Patients with coexistent prothrombotic states often additionally require anticoagulant therapy. Belimumab (Benlysta®, GSK, USA) is a monoclonal antibody that inhibits the B cell survival factor BLyS, which is thought to play a critical role in some patients with SLE. Studies of Belimumab have shown benefit in musculoskeletal and cutaneous manifestations of SLE [19] .
Scleroderma and Mixed Connective Tissue Disease
SSc is a rare autoimmune disease in which immune activation results in vasculopathy, fibroblast stimulation, and connective tissue fibrosis. Lower-extremity ulcers are a known complication of longstanding SSc, affecting approximately 4 % of patients and causing significant morbidity [20] . The prevalence of SSc in patients with chronic wounds is 2.35 % compared to 0.02 % in the general population (p < 0.001) [6•] . Histologically, fibrin occlusive vasculopathy with intimal thickening and some inflammation is seen [20] . SSc ulcers are bilateral in 70 % of cases. Coexistent prothrombotic states contribute to ulceration in SSc, and evaluation for antiphospholipid antibodies and genetic prothrombotic states is recommended. Furthermore, arterial and venous disease can be seen in as many as 50 % of SSc-associated ulcers; therefore, vascular evaluation is recommended in all patients [21] . While vascular interventions play a role in the management of distal ischemia in SSc, the long-term effectiveness of bypass surgery is limited due to small-vessel vasculopathy and studies show high rates of graft failure and limb loss [22] . Medical interventions focused on the vasculopathic etiology of SSc-associated digital ulcers include vasodilators such as calcium channel blockers, prostanoids, and endothelin receptor antagonists.
Topical and systemic opioids are often used to address the severe pain that patients experience with these vasculopathic ulcers, but it should be noted that retrospective data on postoperative wound dehiscence [14•] and longitudinal data from the Wound Healing and Etiology (WE-HEAL) Study have shown that in a more general population with wound issues, higher opioid exposure is associated with slower wound healing. For this reason, cautious dosing should be considered when utilizing opioids in patients with chronic wounds.
Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis resulting in cutaneous ulceration [23] . Lesions typically develop rapidly, with ulceration of a pustule or bulla and development of necrotic borders, purulent drainage, surrounding inflammation, and erythema. Classically, PG lesions exhibit pathergy, with increasing inflammation in response to surgical debridement or biopsy. Often, an underlying systemic immune disease, such as inflammatory bowel disease, psoriasis, or ankylosing spondylitis, can be identified. PG has also been described in association with hematologic diseases including acute and chronic myelogenous leukemia, hairy cell leukemia, myelodysplasia, and IgA monoclonal gammopathy. While there are no specific diagnostic tests, the diagnosis hinges on a typical history along with the finding of neutrophilic infiltration in the dermis, in the absence of infection. Cytokine drivers of PG have been recognized, and treatment targeted at the underlying immune dysfunction in specific cases is recommended [24, 25] .
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis and Leg Ulceration
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA), and the Churg-Strauss syndrome (CSS). Vasculitic leg ulcers are reported in association with all three of these forms of systemic vasculitis, as well as other forms of systemic vasculitis [26, 27] . In cases with negative serology, tissue biopsy is often helpful to confirm the diagnosis [26] . Biopsy should include the subcuticular tissue, and biopsy of early lesions is often most informative [28] . Histologic findings include leukocytoclastic vasculitis with infiltration of arterioles and postcapillary venules by neutrophils undergoing degranulation and fragmentation. Fibrinoid necrosis of the involved vessels and involvement of medium and small arteries of the reticular dermis and fat help confirm the diagnosis.
Direct immunofluorescence is recommended to identify immunoglobulin and complement deposits. As with ulcers caused by other autoimmune etiologies, aggressive treatment of the underlying autoimmune disease often results in healing of the wound [27, 29] . With the advent of B cell depletion therapy for ANCA-associated vasculitis, several authors have reported successful treatment of vasculitic leg ulcers with rituximab (Rituxan®, Genentech) [29, 30] .
Thromboangiitis Obliterans (Buerger's Disease)
Thromboangiitis obliterans (Buerger's disease) is a non-atherosclerotic, segmental inflammatory occlusive disease of small-to medium-sized arteries and veins, most often triggered by exposure to cigarette smoke. The disease may affect arteries and veins of the arms, hands, legs, and feet [31] . Ischemia typically starts distally with later progression to ischemia of more proximal arteries. The presenting symptom is usually claudication of the extremities, but rest pain and ischemic ulceration can develop [31] . Other presenting symptoms include splinter hemorrhages, Raynaud's phenomenon, or livedo reticularis.
Unlike most of the autoimmune diseases, Buerger's disease affects men more commonly than women and is strongly associated with cigarette smoking. The prevalence of Buerger's disease among patients with peripheral arterial disease ranges from as low as 0.5-5.6 % in Western Europe, to as high as 45-63 % in India, and up to 80 % in the Jewish population of Ashkenazi ancestry living in Israel. Buerger's disease should be considered in any patient with critical limb ischemia under the age of 50. It should be noted that SSc can sometimes cause vasculopathy without skin changes, referred to as scleroderma sine scleroderma; serologic workup as outlined in Table 1 allows other etiologies to be excluded.
In contrast to other forms of vasculitis, pathologic specimens in Buerger's disease show highly cellular inflammatory occlusive thrombosis but relative sparing of the blood vessel wall and internal elastic lamina. Acute phase reactants including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are usually normal and serologic markers, and autoantibodies are typically negative [31] .
Angiographic features of Buerger's disease include distal segmental occlusive lesions interspersed with normal appearing arteries, with areas of collateralization around the occlusions termed Bcorkscrew collaterals.^Typically, the disease is infrapopliteral in the lower extremities and distal to the brachial artery in the upper extremities. Proximal atherosclerotic lesions are usually absent. It should be noted that the segmental occlusive disease seen in Buerger's can also be seen in the autoimmune and vasculitic diseases described above, including RA, SSc, and SLE, so these diseases should be ruled out serologically before attributing lesions to Buerger's disease [31] .
Although smoking appears to be a major inciting factor in Buerger's disease, the pathologic mechanisms underlying this condition remain unclear. It has been postulated that smoking may cause delayed hypersensitivity or toxic angiitis. An association between periodontitis and smoking has been found, and bacterial DNA has been detected in the thrombotic samples. Others have postulated a role for endothelial cell antibodies in the pathogenesis of this disease and impaired endotheliumdependent vasodilation in the peripheral vasculature [31] .
The mainstay of treatment for Buerger's disease is smoking cessation, which has been shown to reduce the risk of limb amputations and slow progression of the disease. Nicotine replacement therapy should be used with caution and only as a bridge to smoking cessation since it can lead to ongoing tissue injury.
Infections Associated with Vasculitic and Chronic Wounds
Several chronic infections are associated with cutaneous ulcerations and should be included in the differential when evaluating a patient with a chronic wound who is not responding to usual therapy.
Hepatitis C can cause essential mixed cryoglobulinemia (type II cryoglobulinemia), which can result in an immune complex-mediated small-to-medium vessel vasculitis and ulceration. As with the ANCA-associated vasculitides, B celldirected therapy with rituximab has been shown to be an effective treatment for these patients [32] . Treatment of the hepatitis C using novel anti-viral agents is also effective in these patients [33] .
Hepatitis B is associated with polyarteritis nodosa (PAN), which can sometimes present with an isolated cutaneous vasculitis [34] . While idiopathic PAN requires systemic immunosuppression, the mainstay of management of hepatitis Bassociated PAN involves anti-viral therapy. Patients with chronic wounds that have not responded to usual therapy should be screened for hepatitis B and C as outlined in Table 1 .
Non-tuberculous mycobacteria can also cause chronic wounds. While first described in Africa as the Buruli ulcer, these lesions can be seen in Australia and the USA. If this diagnosis is being considered, it is imperative to request tissue biopsy with appropriate handling by the microbiology laboratory in order to ensure that the diagnosis can be made since atypical mycobacteria are slow growing and grow only under very specific culture conditions [35] .
Erythema Nodosum and Panniculitis
Panniculitis is an inflammatory disease of subcutaneous adipose tissue that may result in induration and ulceration. Several pathologies can result in panniculitis of the lower extremities including nodular vasculitis, erythema nodosum, erythema induratum, pancreatic disease, and α-1 anti-trypsin deficiency [36] . Erythema induratum may present with tender nodules and plaques on the anterior or posterior calf that ulcerate and drain. These lesions are more common in young-and middle-aged women [36] . Biopsy shows mixed septal and lobular inflammatory infiltrate with vasculitis. The differential diagnosis includes TB, sarcoidosis, and certain medications (e.g., sulfonamides and oral contraceptives).
Pancreatic panniculitis may develop in benign or malignant pancreatic disease. Patients present with painful subcutaneous nodules on the lower extremities and trunk that ulcerate with suppurative or oily drainage. Many patients have associated systemic symptoms including fever, abdominal pain, arthritis, ascites, and pleural effusions. Histologic examination reveals septal and lobular inflammation along with characteristic Bghost cells^which are pathognomic for saponification of the adipose tissue seen in pancreatic panniculitis [36] .
α-1 Anti-trypsin deficiency is associated with neutrophilic panniculitis in which tender erythematous and purpuric nodules develop on the trunk and lower extremities. These lesions ulcerate and drain oily discharge and result in scarring as they heal. Pathology shows neutrophilic infiltrate of the adipose tissue with necrosis and destruction of the fat lobules. Diagnosis is confirmed with serum α-1 anti-trypsin activity and genotyping [36] .
Sickle Cell-Associated Leg Ulcers
Sickle cell disease (SCD) is an inherited hemoglobinopathy. Patients that are homozygous for hemoglobin S develop recurrent painful vaso-occlusive and hemolytic crises. Leg ulcers are a frequent complication of SCD and other hemoglobinopathies [37] affecting 2.5 % of patients over 10 years old in the Cooperative Study of Sickle Cell Disease. Ulcer development is correlated with parameters of ongoing hemolysis such as low steady-state hemoglobin and high lactate dehydrogenase (LDH). Presence of HbF appears to be protective. This, combined with perfusion studies, suggests that ulceration in SCD may not be purely a vaso-occlusive process but more likely vasculopathy driven by an inflammatory state related to chronic hemolysis.
Hydroxyurea-Associated Leg Ulcers
One of the most commonly used treatments for SCD is hydroxyurea. Hydroxyurea is an anti-metabolite that inhibits DNA repair by inhibiting ribonucleotide reductase, and it is used in SCD to increase HbF production, thereby reducing the proportion of sickle hemoglobin. While hydroxyurea is generally well tolerated, it is known to be associated with dermatologic side effects including alopecia, diff use hyperpigmentation, erythema, skin atrophy, an amyopathic dermatomyositis, nail changes, poikilodermatous dermatitis, and resistant leg ulcers. Leg ulceration is seen in approximately 9 % of patients receiving hydroxyurea in the setting of myeloproliferative syndromes and in approximately 29 % of patients taking hydroxyurea for management of sickle cell anemia [38] . This complication seems to be dose dependent, with studies reporting an association with a mean cumulative exposure to hydroxyurea of 3.2 kg (range 1.4 to 5.5) and a mean duration of hydroxyurea treatment of 6.1 years (range 2 to 15). Biopsy specimens have shown nonspecific changes, with one series reporting epidermal atrophy, dermal fibrosis, and occasional fibrin occlusive vasculopathy similar to that seen in livedoid vasculitis [39] . The only effective therapy for these ulcers has been withdrawal of hydroxyurea [39, 40] . In many cases, the underlying hematologic disease precludes this. However, the introduction of oral Janus kinase inhibitors for treatment of polycythemia has been successful in some patients [41] .
Occlusive Diseases Resulting in Ulcers
Several diseases can be associated with occlusion of dermal vessels with thrombi or other occlusive material (such as cholesterol emboli or immune complexes). These ulcers are usually acute in onset and exquisitely painful, but characteristically, the patient has intact pulses. Careful evaluation including autoimmune and prothrombotic workup as outlined in Table 1 along with histopathology is recommended.
Atrophie Blanche or Livedoid Vasculopathy
Atrophie blanche or LV is a chronic small-vessel occlusive vasculopathy in which there are recurrent leg ulcers that heal with stellate porcelain white scars. Lesions are often bilateral, involving the dorsal ankle and foot. Atrophie blanche and LV are more common in women [42] . Reported etiologies for LV include autoimmune diseases [43] [44] [45] [46] [47] [48] [49] [50] [51] , hypercoagulable states, and situations with impaired fibrinolysis [52] . However, approximately one third of cases are idiopathic. On biopsy, characteristic pathologic findings include the presence of hyaline thrombi in the mid and upper dermal vessels with fibrinoid changes. In many cases, the characteristic skin lesions can be identified by clinical appearance, and unless there is concern for other etiologies, we rarely recommend biopsy since this can result in further issues with wound healing.
Cholesterol Emboli
Cholesterol emboli should be considered as a potential explanation for leg ulceration in patients with recent history of endovascular procedures. Patients present acutely with painful livedo reticularis and gangrene of a digit or limb-a syndrome commonly referred to as Bblue toe syndrome^ [53, 54] . This syndrome is more common in men over 50 with atherosclerosis, and often, there is a history of recent (hours to days) arterial manipulation. The syndrome is also described as being precipitated by initiation of anti-coagulation; however, this relationship has not been well delineated. Histopathology of affected skin and tissue demonstrates elongated cholesterol clefts in the deep dermal arterioles. However, it is important to specifically ask pathologists to search for this finding in biopsy specimens if this diagnosis is being considered. The mortality of cholesterol emboli syndrome is high. Treatment includes removal or stenting of unstable atheromatous plaques as well as initiation of statins [17] .
Calciphylaxis
Calciphylaxis refers to the calcific uremic arteriolopathy seen in patients with renal failure. It results in progressive occlusion of dermal vessels and manifests with acutely painful, indurated plaques that develop necrosis and ulceration. Calciphylaxis carries a poor prognosis with less than 50 % 1-year survival [55] . Diagnosis requires full-thickness biopsy of an involved region, and the histopathologic finding of calcium deposition in the media of adipose vasculature is required to make the diagnosis. Peri-eccrine calcium deposition is a specific but not sensitive finding. Treatments focused on surgical wound debridement and lowering the calcium phosphate product have some benefit, but parathyroidectomy is generally not effective. Numerous other treatments including sodium thiosulfate have been tried for this condition but with conflicting results [56, 57] .
Cryoglobulin
Cryoglobulins are immune complexes that precipitate at temperatures below 37°C. There are several types. Type I cryoglobulins are usually IgM class and are associated with hematologic malignancies such as Waldenstrom macroglobulinemia and multiple myeloma. Patients with this type of cryoglobulinemia develop symptoms of hyperviscosity and acral purpura, especially in cold weather. Histopathologic examination shows bland hyaline thrombi or red cell occlusion of superficial dermal vessels.
Types II and III are mixed cryoglobulins; i.e., they are composed of monoclonal or polyclonal immunoglobulins, often with rheumatoid factor activity (recognizing the Fc portion of IgG). These types of cryoglobulins are associated with chronic viral infections (such as hepatitis B and C and HIV) and with autoimmune diseases (lupus, RA, Sjogren's syndrome). Both type II and III mixed cryoglobulinemia may present with cutaneous ulceration and a prodrome of arthralgias, myalgias, and fatigue. Cryoglobulins are easily missed unless blood is drawn into collection tubes that have been prewarmed to 37°C without anti-coagulants. After clotting at 37°C for 1 h, the serum is then separated by centrifugation at 37°C and placed in a graduated (Wintrobe) tube at 4°C for 3 to 5 days to allow precipitation of the cryoglobulin.
Prothrombotic Wounds Anti-Phospholipid Syndrome
Leg ulceration in conjunction with painful livedo reticularis, splinter hemorrhages, leg ulcers, superficial thrombophlebitis, and focal ischemia should raise suspicion for antiphospholipid antibody syndrome (APLS). Anti-phospholipid antibodies react with the phospholipid portion of the prothrombin activator complex resulting in occlusion of the small dermal vessels [58] . Treatment with anti-coagulants, particularly those with an anti-fibrinolytic action, is beneficial for healing of these lesions and prevents further thrombosis.
Genetic Prothrombotic States
Genetic prothrombotic states and coagulopathies are a recognized comorbidity in young patients with leg ulcers [59] and patients with LV. Using a correlative animal model, we have been able to demonstrate the impact that these prothrombotic states have on skin graft failure [60] . In patients with refractory chronic wounds, genetic prothrombotic workup (Table 1) is warranted, and evidence from small studies supports use of fibrinolytic agents and anti-coagulation in patients with LV or other wounds with an associated prothrombotic state [61, 62] .
Conclusions
Vasculitic and prothrombotic etiologies should be considered in patients with chronic wounds who do not respond to appropriate vascular intervention and wound management. A collaborative approach with the involvement of dermatology and rheumatology allows investigation for underlying systemic disease contributing to delayed wound healing in these cases. When vasculitis is in the differential diagnosis and a biopsy is planned, the team should be careful to include reticular dermis and subcutaneous tissue. A methodical approach with meticulous history and physical exam along with laboratory workup (as outlined in Table 1 ) improves clinical outcomes for many of these challenging patients.
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